India, April 21 -- Johnson & Johnson (JNJ) Monday announced that it is set to present pivotal data from its oncology pipeline at the American Urological Association or AUA 2025 Annual Meeting in Las Vegas, from April 26-29.
Key highlights include a 12-month duration of response - DOR results from the Phase 2b SunRISe-1 study assessing TAR-200, an intravesical gemcitabine-releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer or HR-NMIBC with carcinoma in situ or CIS. These findings will be featured in a high-profile plenary session focused on transformative clinical trials in urology.
TAR-200, which delivers sustained therapy directly into the bladder, has shown promising complete response rates. ...